🚀 VC round data is live in beta, check it out!
Mesa Laboratories Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mesa Laboratories and similar public comparables like Beta Bionics, Tactile Medical, Anteris Technologies US, Cytek Biosciences and more.
Mesa Laboratories Overview
About Mesa Laboratories
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Founded
1982
HQ
Employees
730
Website
Financials (LTM)
EV
$721M
Mesa Laboratories Financials
Mesa Laboratories reported last 12-month revenue of $251M and EBITDA of $61M.
In the same LTM period, Mesa Laboratories generated $158M in gross profit, $61M in EBITDA, and $16M in net income.
Revenue (LTM)
Mesa Laboratories P&L
In the most recent fiscal year, Mesa Laboratories reported revenue of $241M and EBITDA of $57M.
Mesa Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $251M | XXX | $241M | XXX | XXX | XXX |
| Gross Profit | $158M | XXX | $151M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $61M | XXX | $57M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $16M | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | 6% | XXX | (1%) | XXX | XXX | XXX |
| Net Debt | — | — | $151M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mesa Laboratories Stock Performance
Mesa Laboratories has current market cap of $569M, and enterprise value of $721M.
Market Cap Evolution
Mesa Laboratories' stock price is $103.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $721M | $569M | 0.0% | XXX | XXX | XXX | $-0.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMesa Laboratories Valuation Multiples
Mesa Laboratories trades at 2.9x EV/Revenue multiple, and 11.8x EV/EBITDA.
EV / Revenue (LTM)
Mesa Laboratories Financial Valuation Multiples
As of April 19, 2026, Mesa Laboratories has market cap of $569M and EV of $721M.
Equity research analysts estimate Mesa Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mesa Laboratories has a P/E ratio of 36.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $569M | XXX | $569M | XXX | XXX | XXX |
| EV (current) | $721M | XXX | $721M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 11.8x | XXX | 12.7x | XXX | XXX | XXX |
| EV/EBIT | 11.9x | XXX | 13.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | 4.8x | XXX | XXX | XXX |
| P/E | 36.3x | XXX | (288.5x) | XXX | XXX | XXX |
| EV/FCF | 19.4x | XXX | 16.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mesa Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mesa Laboratories Margins & Growth Rates
Mesa Laboratories' revenue in the last 12 month grew by 5%.
Mesa Laboratories' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Mesa Laboratories' rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mesa Laboratories' rule of X is 37% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Mesa Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 29% | XXX | 30% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mesa Laboratories Public Comps
See public comps and valuation multiples for other Medical Devices and Test & Measurement comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mesa Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Beta Bionics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tactile Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Anteris Technologies US | XXX | XXX | XXX | XXX | XXX | XXX |
| Cytek Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroPace | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mesa Laboratories M&A Activity
Mesa Laboratories acquired XXX companies to date.
Last acquisition by Mesa Laboratories was on XXXXXXXX, XXXXX. Mesa Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mesa Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMesa Laboratories Investment Activity
Mesa Laboratories invested in XXX companies to date.
Mesa Laboratories made its latest investment on XXXXXXXX, XXXXX. Mesa Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mesa Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mesa Laboratories
| When was Mesa Laboratories founded? | Mesa Laboratories was founded in 1982. |
| Where is Mesa Laboratories headquartered? | Mesa Laboratories is headquartered in United States. |
| How many employees does Mesa Laboratories have? | As of today, Mesa Laboratories has over 730 employees. |
| Who is the CEO of Mesa Laboratories? | Mesa Laboratories' CEO is Gary M. Owens. |
| Is Mesa Laboratories publicly listed? | Yes, Mesa Laboratories is a public company listed on Nasdaq. |
| What is the stock symbol of Mesa Laboratories? | Mesa Laboratories trades under MLAB ticker. |
| When did Mesa Laboratories go public? | Mesa Laboratories went public in 1984. |
| Who are competitors of Mesa Laboratories? | Mesa Laboratories main competitors are Beta Bionics, Tactile Medical, Anteris Technologies US, Cytek Biosciences. |
| What is the current market cap of Mesa Laboratories? | Mesa Laboratories' current market cap is $569M. |
| What is the current revenue of Mesa Laboratories? | Mesa Laboratories' last 12 months revenue is $251M. |
| What is the current revenue growth of Mesa Laboratories? | Mesa Laboratories revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Mesa Laboratories? | Current revenue multiple of Mesa Laboratories is 2.9x. |
| Is Mesa Laboratories profitable? | Yes, Mesa Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mesa Laboratories? | Mesa Laboratories' last 12 months EBITDA is $61M. |
| What is Mesa Laboratories' EBITDA margin? | Mesa Laboratories' last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Mesa Laboratories? | Current EBITDA multiple of Mesa Laboratories is 11.8x. |
| What is the current FCF of Mesa Laboratories? | Mesa Laboratories' last 12 months FCF is $37M. |
| What is Mesa Laboratories' FCF margin? | Mesa Laboratories' last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Mesa Laboratories? | Current FCF multiple of Mesa Laboratories is 19.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.